Cannabis and the R&D Tax Credit: What Rescheduling Really Unlocks

August 26, 2026

Photo by Firmbee via Pixabay.

Rescheduling happened. That much is real, and it went into effect on April 28, 2026. But the version of rescheduling that actually took effect is a lot narrower than the headlines suggested last spring. Only marijuana used in FDA-approved drug products and marijuana handled by state-licensed medical programs moved from Schedule I to Schedule III. Everything else -- every adult-use dispensary, every recreational cultivator, every vertically integrated operator selling to the general public -- is still sitting exactly where it was, on Schedule I, alongside other Schedule I substances as far as federal law is concerned.

That distinction matters because Section 280E, the tax code provision that has been quietly strangling cannabis company balance sheets for over a decade by barring ordinary business expense deductions, only lifts for the slice of the industry that actually moved. Adult-use operators get nothing from this round of changes, at least not yet. But for the companies that do qualify -- state-licensed medical marijuana businesses and FDA-approved cannabinoid drug manufacturers -- a door just opened that's been bolted shut since 280E started being applied to cannabis: access to the federal Research and Development tax credit. This piece walks through who actually qualifies under the new rules, what that credit could realistically be worth, and what smart operators should be doing right now, while Treasury and the IRS are still writing the fine print.

The Rescheduling Timeline, and Why It's Still Unfinished

Photo via Unsplash.

This all traces back to an executive order Trump signed on December 18, 2025, directing federal agencies to accelerate research into medical marijuana and CBD. That order didn't reschedule anything by itself, but it set the machinery in motion. Acting Attorney General Todd Blanche and the DEA followed up with a joint order on April 23, 2026, and days later the DEA's final order took effect, moving marijuana in FDA-approved drug products and state-licensed medical marijuana programs to Schedule III as of April 28, 2026.

What didn't happen is a full, industry-wide reclassification. A separate administrative hearing on the Department of Justice's broader proposal to move marijuana to Schedule III across the board opened June 29, 2026, in front of Chief Administrative Law Judge Derek C. Julius. Seven participants were selected to present arguments, and by most accounts every one of them opposed rescheduling. That hearing wrapped on July 15, and closing briefs are still being finalized as of this writing, with no ruling issued yet.

If things move at a brisk pace, a Final Rule could land sometime in late 2026 or early 2027. That's an optimistic read, not a promise. Administrative rulemaking of this scale has a habit of slipping, and opposition testimony at the hearing gives Judge Julius plenty of material to work through before issuing recommended findings. Until there's a final decision, full-plant, adult-use marijuana remains a Schedule I substance under federal law, which means most of the cannabis industry -- the recreational dispensaries, the adult-use cultivators, the multi-state operators selling to anyone over 21 -- hasn't moved an inch. Anyone building a tax strategy around rescheduling needs to be precise about which sliver of the plant, and which type of license, the current rule actually covers.

Section 280E: Who's Actually Free of It Now

Section 280E has been the single most punishing feature of federal cannabis tax law since it started getting applied to state-legal operators. Written originally to stop drug traffickers from deducting business expenses, it treats a licensed dispensary the same way it treats a cartel: no deduction for rent, payroll, marketing, or nearly anything else, because the business traffics in a Schedule I or II controlled substance. Companies in virtually every other industry get to deduct ordinary costs before calculating taxable income. Cannabis companies subject to 280E have had to pay tax on something closer to gross revenue.

Treasury's own press release accompanying the rescheduling rollout confirmed the mechanism at work here: rescheduling removes 280E as a bar to deductions and credits, but only for businesses that no longer traffic in a Schedule I or II substance. Since the DEA's order only reclassified marijuana in FDA-approved drug products and state-licensed medical programs, those are the only operators who actually escape 280E. Think companies producing cannabinoid drugs along the lines of Epidiolex, and state-licensed medical marijuana businesses operating strictly within their medical programs.

Recreational and adult-use companies get none of this relief, even if they're operating out of the same building, under the same ownership, as a qualifying medical business. And that creates a genuinely thorny problem for the dual-licensed operators common in hybrid medical/adult-use states -- California, Michigan, and Massachusetts among them. These companies now have to evaluate their activities at the business component level, likely maintaining separate accounting for medical operations that qualify and adult-use operations that don't. Sloppy recordkeeping here isn't just inconvenient; it risks disqualifying costs that should have been deductible.

How the R&D Credit Actually Works for Cannabis Companies

R&D tax credits typically offset between 5% and 10% of qualifying research and development expenses, meaning businesses can recoup up to a tenth of their eligible R&D spending.

The federal R&D credit isn't exotic tax policy -- it's been a long-standing part of the tax code, and it typically returns somewhere between 5% and 10% of a company's qualifying domestic research expenses, with employee salaries usually making up the biggest chunk of the calculation. For a cannabis company doing real formulation or cultivar work, that's not a rounding error.

Qualifying research generally has to be technical and experimental, aimed at resolving genuine uncertainty about how to develop or improve a product or process. In the cannabis context, that covers a fair amount of ground: extraction method development, formulation science for tinctures or topicals, cultivar breeding programs targeting specific cannabinoid or terpene profiles, and dosing and delivery research for medical products. None of that is hypothetical work -- companies in the medical and pharmaceutical-grade cannabis space have been doing exactly this kind of research for years. They just couldn't get any tax benefit from it, because 280E blocked the deduction chain the credit depends on, even when the underlying research would have otherwise qualified under the standard four-part test.

There's a second layer of benefit here too. Pass-through entities that now sit on Schedule III also gain access to the 20% Qualified Business Income deduction under Section 199A, which stacks on top of whatever R&D credit a company claims. Combined, these two provisions represent the first real federal tax relief pathway available to any part of this industry.

Major advisory firms have noticed. Withum, Crowe, MGO, and CohnReznick are all reportedly advising cannabis clients to start tracking qualifying research activity now, rather than waiting for the IRS to publish detailed guidance. Given how new this territory is, that's sound advice -- there's no established playbook yet, and the companies building documentation habits early will have a real head start.

What Companies Should Do While Guidance Is Still Pending

Photo via Pexels.

Treasury and the IRS still owe the industry meaningful guidance, particularly on how companies should apportion expenses when they run both qualifying and non-qualifying operations side by side. Until that guidance lands, a lot of the fine detail remains genuinely unsettled.

One piece that is expected: a transition rule applying relief starting with the first full taxable year that includes April 22, 2026. For companies on a calendar tax year, that's straightforward enough. For companies with fiscal years that don't line up neatly with the calendar, figuring out exactly which tax year triggers eligibility is going to take some careful calendar math with a tax advisor, not guesswork.

In the meantime, businesses with open tax years can consider filing protective refund claims to preserve their right to retroactive relief if final guidance ends up more favorable than expected. That's a real strategy, not a hypothetical one -- but it needs to be executed carefully. The IRS has a track record of pushing back hard on amended returns and refund claims filed prematurely or without adequate substantiation, and cannabis companies in particular have drawn extra scrutiny historically. This is not a do-it-yourself form you print off and mail in.

Practically speaking, there are a few things worth doing before year-end regardless of how the final guidance shakes out. Start contemporaneous documentation of research activities and their associated costs now -- timesheets, project notes, lab records, anything that ties personnel hours to specific research questions. If your company operates both medical and adult-use lines, set up separate ledgers now rather than trying to reconstruct the split later. And loop in a tax professional or tax attorney who actually has cannabis industry experience, because general tax guidance won't capture the nuances of 280E, Schedule III eligibility, and the R&D credit interacting all at once.

It's worth being blunt about the size of this opening: it's narrow. Only state-licensed medical marijuana businesses and FDA-approved cannabinoid drug makers benefit from any of this right now. The bulk of the industry -- every adult-use dispensary and recreational cultivator in the country -- is still waiting on Judge Julius's administrative process and whatever Final Rule eventually emerges from the DEA's broader Schedule III proceeding, a decision that could still be a year or more away.

Companies that start building documentation habits today, rather than waiting for that Final Rule to arrive, are going to be in a materially stronger position. Protective claims and transition rules both tend to reward the businesses that were already keeping clean records when the guidance finally caught up to them. Waiting until the rules are fully settled to start tracking research costs means losing months, maybe years, of eligible activity that simply won't be reconstructable after the fact.

None of this substitutes for professional advice tailored to your specific situation. State cannabis law varies enormously, federal rescheduling status is still moving, and the interaction between 280E, Schedule III eligibility, and the R&D credit is genuinely new legal and tax territory. Talk to a qualified tax professional with real cannabis industry experience before making any filing decisions -- and check back on where things stand often, because this landscape is shifting month to month right now, not year to year.